Tag: major bleeding

1. Guided selection of antiplatelet therapy reduced rates of major adverse cardiovascular event rates compared to standard therapy. 2. Guided selection strategy was beneficial for both escalation and de-escalation of standard therapy, balancing patient-dependent ischemic and bleeding risks.  Evidence Rating Level: 1 (Excellent) Study Rundown: Patients who undergo percutaneous coronary intervention (PCI)...
1. There was no significant difference in periprocedural myonecrosis between ticagrelor and clopidogrel among patients undergoing high-risk elective PCI. 2. Ticagrelor treatment was associated with an increased rate of minor bleeding at 30 days post-operation. Evidence Rating Level: 1 (Excellent) Study Rundown: Percutaneous coronary intervention (PCI) provides a safe therapeutic option for patients with...
1. Patients status-post placement of drug-eluting stents (DES) for acute coronary syndrome received three months of Ticagrelor and Aspirin dual-antiplatelet therapy (DAPT), followed by nine months of DAPT or Ticagrelor monotherapy. 2. At one year, patients who received Ticagrelor alone experienced significantly fewer adverse major bleeding events. There was no...
1. In this retrospective cohort study conducted in Michigan, aspirin therapy combined with warfarin for patients without a clinical indication was associated with increased rates of major bleeding, emergency visits for bleeding, and hospital admissions for bleeding. 2. Among these patients, there was no difference in rates of thrombosis or...
1. In this systematic review and meta-analysis, while aspirin use among patients without cardiovascular disease was associated with fewer adverse cardiovascular events, it was not associated with a reduction in all-cause mortality. 2. The use of aspirin in patients without cardiovascular disease was associated with increased risk of major bleeding. Evidence Rating...
The risk of venous thromboembolism (VTE) is significantly increased in patients with active cancer. While parenteral prophylactic anticoagulation has been shown to reduce the risk of VTE in cancer patients, its use is associated with an increased risk of major bleeding and the inconvenience of daily injections. Direct oral...